- Trial Phase
- Phase 3
- Time to Market
- At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
- Why 4/10
- No hard dated binary catalyst in the next ~12 months. The Phase 3 BATTMAN trial (NCT07152821) began enrollment in April 2026 but uses a survival endpoint that will take years to mature. The FDA rejected accelerated approval in 2025-2026. ImpactScore reflects botensilimab being Agenus' lead/defining asset but lacking any near-term PDUFA or pivotal readout.
Agenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial — the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.
Price Chart
Executive Summary
Botensilimab is Agenus' lead asset — an Fc-enhanced anti-CTLA-4 antibody designed to outperform Yervoy (ipilimumab). It has shown durable responses in nine difficult-to-treat metastatic cancers, with notable 33-42% survival rates at 2-3 years in refractory MSS colorectal cancer, a population typically resistant to immunotherapy. However, the FDA rejected an accelerated approval pathway, requiring a full Phase 3 trial that began enrollment in April 2026. Agenus just announced a heavily dilutive ~$85M PIPE financing (July 13, 2026) to fund the Phase 3 trial. The stock trades near its 52-week low with high short interest (~14.4% of shares outstanding), reflecting skepticism about the long timeline and dilution.
How It Works
Botensilimab is a next-generation antibody that targets CTLA-4, a protein on immune cells that acts as a 'brake' on the immune system. Unlike the older CTLA-4 drug Yervoy (ipilimumab), botensilimab has been genetically engineered to also help the immune system kill suppressor cells inside tumors. It is typically combined with balstilimab, a PD-1 inhibitor that removes a different immune brake. The goal is to 'release the brakes' on the immune system to attack cancer, including hard-to-treat tumors that don't respond to standard immunotherapy.
Trial Status
The global Phase 3 BATTMAN trial (NCT07152821) evaluating botensilimab + balstilimab vs best supportive care in refractory MSS/pMMR metastatic colorectal cancer enrolled its first patient in April 2026. Phase 1b and Phase 2 studies have been completed across nine tumor types with ~1,300 patients treated. A Phase 2 study in metastatic pancreatic cancer (NCT05630183) completed enrollment (81 patients). Multiple Phase 2 trials in melanoma, ovarian cancer, sarcoma, and gastroesophageal cancer are ongoing or recently reported data at ASCO/AACR 2026.
The Two-Sided Case
Upcoming Catalysts
- ESMO GI 2026 (late June/July 2026) — three-year survival data from Phase 1b MSS CRC study already announced top-line; full presentation may provide detail
- Ongoing Phase 2 data readouts across melanoma, ovarian, pancreatic, and sarcoma indications through 2026-2027
- Pathological complete response (pCR) data trigger from Phase 3 BATTMAN (≥50 patients) — the milestone that accelerates Series B warrant expiration per the PIPE terms
- Potential business development/partnership — the Zydus collaboration ($91M upfront closed in 2025) demonstrates ability to non-dilutively fund development
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AGENUS INC 8-K AGEN ·Originating report